Awakn Life Sciences Corp. announced it has signed its fourth Licensing Partnership agreement in North America. The agreement is with Ken Starr MD Wellness Group an addiction treatment facility in California.

This is the first Licensing Partnership Awakn has signed with a dedicated addiction treatment provider. Awakn will provide access to, and training for its proprietary therapeutics package 'Awakn Kare' to Ken Starr practitioners. Under the terms of the agreement Ken Starr MD Wellness Group will pay Awakn a fee and a revenue share per treatment.

Awakn Kare is a proprietary treatment protocol developed and validated in a Phase II a/b trial. The trial delivered 86% abstinence over the six-months post-treatment versus 2% pre-trial. This efficacy is significantly better than the current standard of care for AUD which has an approximate 25% abstinence rate over a similar timeframe.

The U.S. alcohol and substance addiction treatment industry is significant in size with 14,000+ treatment facilities across the country. Traditional AUD rehabilitation facilities range in cost nationally from USD 20,000 to USD 65,000 per month, generating more than $35 billion in revenue, even with their low efficacy rates. Awakn aims to improve performance of the addiction industry by providing clinic operators with access to an efficient and more effective treatment option under license.